Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1004 (IMP1707) monotherapy in advanced solid tumors (Phase 1/2 dose escalation and optimization)
2024-520395-99-00Phase 2Authorised
- Sponsor
- Eikon Therapeutics
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of EIK1004 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 3 more, sponsored by Eikon Therapeutics. Primary endpoints: Dose-limiting toxicities and Adverse events. Planned start Aug 2025; status: authorised.
02
Drugs
EIK1004
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)breast adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on 2024-520395-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520395-99-00.